Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Cancer Discov. 2019 May 2;9(7):910–925. doi: 10.1158/2159-8290.CD-19-0125

Figure 4. Cells with loss-of-function alleles for TP53, PMAIP1 or BAX have diminished apoptosis in response to venetoclax treatment.

Figure 4.

A and B. Sensitivities to venetoclax in MOLM-13 parental cells (MOLM13P) and MOLM13 cells with sgRNA inactivated alleles, as indicated, was assessed by flow cytometry after staining with the early apoptosis marker, Annexin V, following 24, 48 and 72 hrs of exposure to venetoclax. Histogram represents mean and standard deviation for three replicates of percentage Annexin V+ cells in the total cell population. C. Western blot analysis of proteins extracted from MOLM-13 parental and MOLM-13 cells transduced with indicated sgRNA/Cas9 viruses and treated overnight with 100 nM venetoclax or vehicle (DMSO), and identified with antisera to phosphorylated ERK1/2 (Thr202/Tyr204, pERK1/2), ERK1/2, phosphorylated AKT (Thr308), AKT and GAPDH.